Meta-analysis of the prognostic value of lncRNA ZFAS1 in patients with solid tumors

Wei Song, Chuan Tian, Run-Jin Zhang, Shu-Bing Zou _ and Kai Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:90301-90307. https://doi.org/10.18632/oncotarget.19566

Metrics: PDF 1246 views  |   HTML 2152 views  |   ?  


Wei Song1,*, Chuan Tian2,*, Run-Jin Zhang1, Shu-Bing Zou1 and Kai Wang1

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

2Department of Nuclear Medicine, Guizhou Provincial People’s Hospital, Guiyang, China

*These authors contributed equally to this work

Correspondence to:

Shu-Bing Zou, email: [email protected]

Kai Wang, email: [email protected]

Keywords: ZFAS1, long noncoding RNA, cancer, prognosis, meta-analysis

Received: March 22, 2017     Accepted: July 18, 2017     Published: July 26, 2017


Expression of ZFAS1, a newly identified long noncoding RNA (lncRNA), is dysregulated in several types of cancer. Here we assessed the prognostic value of ZFAS1 in solid tumors. A comprehensive literature search was performed by screening the PubMed, EMBASE, MEDLINE, Cochrane Library, CNKI, and Wanfang databases. A total of 874 patients from 10 studies were included. The pooled analysis demonstrated that patients with high ZFAS1 expression had a significantly shorter overall survival (OS) (HR, 1.58; 95% CI, 1.28–1.97; P < 0.001) and recurrence-free survival (RFS) (HR, 1.90; 95% CI, 1.29–2.79; P = 0.001). Moreover, elevated ZFAS1 expression correlated with tumor size, tumor-node-metastasis (TNM) stage, and lymph node metastasis (LNM). These results demonstrate that increased ZFAS1 expression correlates with a poor prognosis in cancer patients, which suggests ZFAS1 might be useful as a potential prognostic biomarker in patients with solid tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19566